Leukodystrophies with abnormal peaks on magnetic resonance spectroscopy pane [4 genes]

Some patients with leukodystrophy show abnormal peaks on magnetic resonance spectroscopy (MRS). Although these peaks are usually non-specific, they can be relevant in some clinical scenarios. In this sense, patients with Sjögren-Larsson syndrome, which produces lipid peaks in white matter, show a characteristic abnormal lipid peak at 1.30 ppm.

On the other hand, patients with cerebrotendinous xanthomatosis show increases in lipid and lactate peaks and decreased N-acetylaspartate levels in the cerebellum. Although these findings are non-specific, since the disease is related to lipid accumulation in the central nervous system, MR spectroscopy can be used as a non-invasive biomarker of response to treatment.

Finally, some patients with leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation may show lactate peaks on MR spectroscopy, thus helping their diagnosis.

Request study Informed consent
Steps to follow
Steps to follow

How to order

1. Download & fill out

Please cover as many fields as possible in both documents

2. Sample collection

Three sample types: saliva, peripheral blood or genomic DNA

3. Pack the sample

Please pack the sample in a way to prevent leakage

4. Send the sample & the request

Please schedule the delivery for Mon–Thur: 8am – 5pm

5. Result: the report

Via: Client Site HIC / Client Site Imegen / Certified email

Ask for information
Solicita información de

Leukodystrophies with abnormal peaks on magnetic resonance spectroscopy pane

"*" indicates required fields

Consentimiento*
This field is for validation purposes and should be left unchanged.

Turnaround time (TAT): 6 weeks

Ref. S-202008614

Leukodystrophies with abnormal peaks on magnetic resonance spectroscopy pane: View panel
  • ALDH3A2
  • CYP27A1
  • DARS2
  • EARS2

Priority Genes : Genes where there is sufficient evidence (clinical and functional) to consider them associated with the disease; they are included in the clinical practice guidelines.
Secondary Genes: Genes related to the disease, but with a lower level of evidence or that constitute sporadic cases.
* Candidate Genes: Not enough evidence in humans, but potentially associated with the disease.

Related panels
Leukodystrophies and other hereditary leukoencephalopathies comprehensive panel [142 genes]

Phenotypes

  • ALDH3A2: Sjögren-Larsson syndrome
  • CYP27A1: Cerebrotendinous xanthomatosis
  • EARS2: Leukoencephalopathy with thalamus and brainstem involvement and high lactate (LTBL)
  • DARS2: Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL)